{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neoadjuvant+therapy&page=2", "query": { "intervention": "Neoadjuvant therapy", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neoadjuvant+therapy&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-15T05:07:14.077Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04919512", "title": "A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urinary Bladder Neoplasms" ], "interventions": [ { "name": "TAR-200", "type": "DRUG" }, { "name": "Cetrelimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 163, "start_date": "2022-07-07", "completion_date": "2026-03-31", "has_results": true, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-09-15T05:07:14.077Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04919512" }, { "nct_id": "NCT07786428", "title": "Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Triple-Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Paclitaxel (Chemotherapy)", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-10-01", "completion_date": "2030-10-31", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-09-15T05:07:14.077Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07786428" }, { "nct_id": "NCT04912063", "title": "Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia (AML)", "Myelodysplastic Syndrome (MDS)" ], "interventions": [ { "name": "Lemzoparlimab", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2021-06-25", "completion_date": "2023-05-09", "has_results": false, "last_update_posted_date": "2024-02-26", "last_synced_at": "2026-09-15T05:07:14.077Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Louisville, Kentucky • Boston, Massachusetts + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04912063" }, { "nct_id": "NCT05520099", "title": "Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Immunotherapy", "Cancer", "Bladder Cancer", "Urothelial Carcinoma Bladder", "Kidney Cancer", "Clear Cell Renal Cell Cancer (ccRCC)", "Colorectal Cancer", "MSI-H Colorectal Cancer", "DMMR Colorectal Cancer", "Head and Neck Cancer (H&N)", "Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)", "Liver Cancer", "Hepatocellular Carcinoma (HCC)", "Lung Cancer (NSCLC)", "NSCLC (Non-small Cell Lung Cancer)", "Skin Cancer", "Cutaneous Melanoma", "Endometrial Cancer", "Solid Tumor Cancer" ], "interventions": [ { "name": "Core Needle Biopsy, Forceps Biopsy, Punch Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Elephas", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 416, "start_date": "2023-06-26", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-09-15T05:07:14.077Z", "location_count": 12, "location_summary": "Little Rock, Arkansas • Salinas, California • Orlando, Florida + 9 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Salinas", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Stuart", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05520099" }, { "nct_id": "NCT02987998", "title": "Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stage IIIA Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Radiation", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nathan Pennell, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2017-05-19", "completion_date": "2022-11-28", "has_results": false, "last_update_posted_date": "2022-12-19", "last_synced_at": "2026-09-15T05:07:14.077Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02987998" }, { "nct_id": "NCT02779855", "title": "Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Ductal Carcinoma", "Invasive Breast Carcinoma", "Invasive Ductal Breast Carcinoma" ], "interventions": [ { "name": "Talimogene laherparepvec", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 50, "start_date": "2017-05-02", "completion_date": "2025-08-26", "has_results": true, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-09-15T05:07:14.077Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02779855" }, { "nct_id": "NCT07764978", "title": "Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Newly Diagnosed Multiple Myeloma" ], "interventions": [ { "name": "AZD0120", "type": "BIOLOGICAL" }, { "name": "Daratumumab", "type": "BIOLOGICAL" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Isatuximab", "type": "BIOLOGICAL" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 750, "start_date": "2026-06-26", "completion_date": "2034-05-12", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-09-15T05:07:14.077Z", "location_count": 45, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 37 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07764978" }, { "nct_id": "NCT00256243", "title": "Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "GM-CSF", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rita Sanghvi, Mehta", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 48, "start_date": "2004-04", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2018-03-02", "last_synced_at": "2026-09-15T05:07:14.077Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00256243" }, { "nct_id": "NCT00017368", "title": "Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "etoposide phosphate", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "isotretinoin", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 42, "start_date": "2001-04", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2014-02-13", "last_synced_at": "2026-09-15T05:07:14.077Z", "location_count": 8, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Portland, Oregon + 4 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Portland", "state": "Oregon" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00017368" }, { "nct_id": "NCT06025747", "title": "A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Retroperitoneal Sarcoma", "Liposarcoma", "Dedifferentiated Liposarcoma" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Therapeutic Surgical Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2025-03-19", "completion_date": "2029-03-03", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-09-15T05:07:14.077Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06025747" } ] }